Haematology trials group

San CTU's first participation in clinical trials commenced in at the Hornsby premises. San CTU is now a well-established and respected clinical trials unit and have participated in over trials.

The purpose of the unit is to provide all oncology and haematology patients treated at Sydney Adventist Hospital the best possible treatment outcomes through offering them the opportunity and ability to participate in the most current treatment options available in the fields of medical oncology, radiation oncology and clinical haematology.

Breast Cancer. Liver Cancer. Chronic Lymphocytic Leukaemia. How to participate in a clinical trial. The group works closely with clinical research networks, funders and researchers to develop research to improve outcomes for haematology cancer patients. The NCRI Haematological Oncology Group consists of an executive group, chaired by Professor Peter Hillmen , which provides oversight of the research landscape and proactively identifies opportunities for the group.

Members are competitively recruited to the executive Group and subgroups twice a year and are advertised on the jobs and opportunities page. The highest aspirations in the fight against cancer are of little worth unless we have the ability to deliver, and deliver well. One of the biggest challenges I have found is that you can have all the best aspirations to bring fantastic treatment to patients, but everything becomes secondary if you cannot execute these expectations.

It allows us the proper framework to do the work that needs to be done. You need proper infrastructure because clinical research involves everything from negotiations with companies, ensuring that data is collected and entered at the highest levels of accuracy, and following all the international regulations and guidelines for safety, efficacy, and ethics.

Observations that drug toxicities were, at times, more severe in our Asian patients spurred this desire to learn more about the Asian phenotype. Since our early start to investigate areas such as this, we have grown strength to strength in developing our research capabilities and interests.

From demonstrating that various chemotherapy regimens for common cancers like breast and lung may result in different levels of side effects as compared with Caucasians, we have developed the international recognition in drug development to lead first-in-man early drug studies.

This has had the additional benefit of offering suitable patients the opportunity to utilise cutting-edge and novel new drugs, long before these become available for routine use. Today, HORG is recognised as being at the forefront of translational research in cancer therapeutics. Our researchers have the support of a committed team of doctors, administrators, clinical trial coordinators, nurse and pharmacists, in conducting their research. This model has helped allow dedicated care for our patients on clinical trials, focusing much needed time and effort where it is necessary, i.

Today, the department is recognised as being at the forefront of translational research in cancer therapeutics. We aim to do better, from nurturing the next generation of investigators to continuing to help develop and increase our understanding of new therapies in Asia. Dr Lim Siew Eng. HORG conducts a number of first-in-man and first-in-class early drug studies. HORG trial unit comprises of a dedicated team of clinical research coordinators, data coordinators, administrators and finance executives.

It manages and supports all aspects of the clinical trial - from securing ethics, regulatory, budget and legal approvals to the conducting of the study.

You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.